RNA Stock Forecast: Atrium Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Atrium Therapeutics, Inc. is $25. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 8 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Atrium Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (83): Analysts have, on balance, been raising their forecasts.
Volatility (4): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
RNA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on RNA, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | $25 → $20 |
| 22 Oct 2026 | Roth Capital | Initiates | Buy | $15 |
| 14 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $25 |
| 6 Aug 2026 | HC Wainwright & Co. | Initiates | Buy | $25 |
| 18 June 2026 | Cantor Fitzgerald | Initiates | Overweight | $25 |
| 15 May 2026 | Leerink Partners | Initiates | Outperform | — |
| 11 Mar 2026 | Wells Fargo | Initiates | Overweight | — |
| 11 Nov 2025 | Chardan Capital | Maintains | Neutral | — |
| 29 Oct 2025 | TD Cowen | Downgrade | Hold | — |
| 28 Oct 2025 | Chardan Capital | Downgrade | Neutral | — |
| 28 Oct 2025 | RBC Capital | Downgrade | Sector Perform | — |
| 27 Oct 2025 | Bernstein | Downgrade | Market Perform | — |
| 27 Oct 2025 | Citigroup | Downgrade | Neutral | — |
| 27 Oct 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 27 Oct 2025 | Leerink Partners | Downgrade | Market Perform | — |
| 27 Oct 2025 | Needham | Downgrade | Hold | — |
| 27 Oct 2025 | Raymond James | Downgrade | Market Perform | — |
| 22 Sept 2025 | Evercore ISI Group | Maintains | Outperform | — |
| 17 Sept 2025 | Roth Capital | Initiates | Buy | — |
| 15 Sept 2025 | B of A Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RNA.
This page is one stock. Monday covers all of them.
RNA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
RNA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 3.8×
- Price / book
- 0.6×
- EV / EBITDA
- —
Cheaper than 28% of US stocks
Cheaper than 85% of US stocks
- Revenue growth (YoY)
- 24.2%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
Higher than 74% of US stocks
- Return on equity
- −95.0%
- Return on assets
- −34.8%
- Dividend yield
- —
Higher than 14% of US stocks
Higher than 12% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Atrium Therapeutics, Inc. has a market value of $149.3M.
Revenue in the twelve months to 30 June 2026: $35.8M.
Net income over the same four quarters: −$93.2M, a −260.0% net margin.
Free cash flow in the twelve months to 30 June 2026: −$56.5M.
Atrium Therapeutics, Inc. employs 511 people — $70K of revenue per employee.
Data provided by Twelve Data
RNA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at RNA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Atrium Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about RNA
What is the RNA stock price forecast for 2026-2027?
The median 12-month analyst price target for Atrium Therapeutics, Inc. is $25, with estimates ranging from $15 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is RNA stock a buy right now?
Of the 5 analysts covering Atrium Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Atrium Therapeutics, Inc. 8 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank RNA?
As at 21 Nov 2026, Atrium Therapeutics, Inc. ranks 8 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (83 of 100).
Will RNA stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts is $25, and Ticker Nerd's factor model ranks Atrium Therapeutics, Inc. 8 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the RNA stock forecast for 2030?
No analyst covering Atrium Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $25 over the next 12 months.
What does Atrium Therapeutics, Inc. do?
Atrium Therapeutics, Inc. is a biopharmaceutical company focused on precision cardiology through targeted RNA therapeutics for heart disease. The company develops therapies designed to deliver ribonucleic acid medicines directly to cardiac tissue, using a proprietary delivery platform that combines tissue-selective targeting with oligonucleotide precision.
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc. is a biopharmaceutical company focused on precision cardiology through targeted RNA therapeutics for heart disease. The company develops therapies designed to deliver ribonucleic acid medicines directly to cardiac tissue, using a proprietary delivery platform that combines tissue-selective targeting with oligonucleotide precision. Its current pipeline centers on rare genetic cardiomyopathies, including ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy. Atrium Therapeutics also advances research programs aimed at additional rare cardiac conditions, reflecting its focus on genetically defined diseases with significant unmet medical need. Based in San Diego, California, Atrium Therapeutics operates as a specialist developer in the broader biotechnology sector, with a business model centered on translating RNA science into potential treatments for inherited heart disorders.
CEO Ms. Kathleen P. Gallagher · 511 employees · United States · https://atriumtherapeutics.com